Clinical observation of the effect of Sacubitril/Valsartan on chronic heart failure and dialysis patients with hypertension complicated with HFmrEF and HFpEF

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100046450

Enrollment

Unknown

Registered

2021-05-15

Start date

2021-05-10

Completion date

Unknown

Last updated

2022-01-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney disease

Interventions

Observation group:sacubitril/valsartan

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Aged >= 18 years; 2. Patients who meet the diagnostic criteria for heart failure SBP >140mmHg or DBP >90mmHg and LVEF% >40% by cardiac color Doppler ultrasound examination, and receive regular dialysis (>3 months) treatment.

Exclusion criteria

Exclusion criteria: Patients who refuse to participate in this trial.

Design outcomes

Primary

Measure	Time frame
NYHA heart function classification;Left ventricular ejection fraction;	—

Secondary

Measure	Time frame
Blood pressure;Heart rate;Hemoglobin;Myocardial enzymes;Left ventricular end diastolic diameter;Left ventricular end systolic diameter;Inner diameter of left atrium;E/A;	—

Countries

China

Contacts

Public ContactDai Chun

Affiliated Hospital of Xuzhou Medical University

1218880700@qq.com+86 18052268638

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026